J M Scherrmann

1.6k total citations
40 papers, 1.2k citations indexed

About

J M Scherrmann is a scholar working on Molecular Biology, Pharmacology and Physiology. According to data from OpenAlex, J M Scherrmann has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 7 papers in Pharmacology and 7 papers in Physiology. Recurrent topics in J M Scherrmann's work include Protein purification and stability (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). J M Scherrmann is often cited by papers focused on Protein purification and stability (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). J M Scherrmann collaborates with scholars based in France, United Kingdom and United States. J M Scherrmann's co-authors include C Bismuth, A. Sabouraud, P. Sandouk, Olivier Chappey, R Bourdon, Pascal Houzé, Pierre‐Edouard Fournier, F. Audebert, Cassian Bon and M Debray and has published in prestigious journals such as Journal of Neurochemistry, Journal of Pharmacology and Experimental Therapeutics and Anesthesiology.

In The Last Decade

J M Scherrmann

38 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J M Scherrmann France 19 481 346 150 143 133 40 1.2k
J.M. Scherrmann France 18 530 1.1× 267 0.8× 75 0.5× 191 1.3× 144 1.1× 53 1.4k
Bo Odlind Sweden 21 287 0.6× 221 0.6× 98 0.7× 176 1.2× 148 1.1× 56 1.4k
Vanya Peltekova Canada 15 476 1.0× 293 0.8× 493 3.3× 134 0.9× 56 0.4× 20 1.7k
Basab K. Mookerjee United States 19 330 0.7× 137 0.4× 39 0.3× 164 1.1× 89 0.7× 54 1.1k
N. Zöllner Germany 21 449 0.9× 558 1.6× 161 1.1× 194 1.4× 72 0.5× 207 1.8k
John C. Rose United States 24 400 0.8× 249 0.7× 69 0.5× 99 0.7× 38 0.3× 90 1.7k
T. Sakuma Japan 18 429 0.9× 124 0.4× 63 0.4× 63 0.4× 83 0.6× 46 1.3k
Marc B. Bailie United States 17 476 1.0× 143 0.4× 61 0.4× 37 0.3× 124 0.9× 44 2.0k
A Gutman Israel 20 343 0.7× 175 0.5× 64 0.4× 298 2.1× 68 0.5× 62 1.2k
W. C. Wise United States 19 345 0.7× 114 0.3× 45 0.3× 68 0.5× 62 0.5× 47 1.3k

Countries citing papers authored by J M Scherrmann

Since Specialization
Citations

This map shows the geographic impact of J M Scherrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J M Scherrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J M Scherrmann more than expected).

Fields of papers citing papers by J M Scherrmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J M Scherrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J M Scherrmann. The network helps show where J M Scherrmann may publish in the future.

Co-authorship network of co-authors of J M Scherrmann

This figure shows the co-authorship network connecting the top 25 collaborators of J M Scherrmann. A scholar is included among the top collaborators of J M Scherrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J M Scherrmann. J M Scherrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carrupt, Pierre‐Alain, et al.. (2013). Methodologies to Assess Drug Permeation Through the Blood–Brain Barrier for Pharmaceutical Research. Pharmaceutical Research. 30(11). 2729–2756. 41 indexed citations
2.
Linares, Célia Lloret, Xavier Declèves, Jean Michel Oppert, et al.. (2009). Pharmacology of Morphine in Obese Patients. Clinical Pharmacokinetics. 48(10). 635–651. 46 indexed citations
3.
Goudemand, Jenny, I. Scharrer, Erik Berntorp, et al.. (2005). Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. Journal of Thrombosis and Haemostasis. 3(10). 2219–2227. 64 indexed citations
4.
Renard, Claire, et al.. (1999). Time- and dose-dependent digoxin redistribution by digoxin-specific antigen binding fragments in a rat model. Toxicology. 137(2). 117–127. 2 indexed citations
5.
Renard, Claire, Olivier Chappey, M.-P. Wautier, et al.. (1997). Recombinant Advanced Glycation End Product Receptor Pharmacokinetics in Normal and Diabetic Rats. Molecular Pharmacology. 52(1). 54–62. 71 indexed citations
6.
Bismuth, C, Frédéric J. Baud, & J M Scherrmann. (1997). The Use of Antibodies As Therapeutic Agents in Toxicology.. Nihon Kyukyu Igakukai Zasshi Journal of Japanese Association for Acute Medicine. 8(5). 175–182.
7.
Rizzo, N., et al.. (1996). Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. European Journal of Clinical Pharmacology. 49(6). 491–495. 23 indexed citations
8.
Chappey, Olivier, M Debray, Elisabeth Niel, & J M Scherrmann. (1994). Association constants of monoclonal antibodies for hapten: heterogeneity of frequency distribution and possible relationship with hapten molecular weight. Journal of Immunological Methods. 172(2). 219–225. 37 indexed citations
9.
Audebert, F., M. Urtizberea, A. Sabouraud, J M Scherrmann, & Cassian Bon. (1994). Pharmacokinetics of Vipera aspis venom after experimental envenomation in rabbits.. Journal of Pharmacology and Experimental Therapeutics. 268(3). 1512–1517. 58 indexed citations
10.
Chappey, Olivier, Elisabeth Niel, Jean‐Luc Wautier, et al.. (1993). Colchicine disposition in human leukocytes after single and multiple oral administration. Clinical Pharmacology & Therapeutics. 54(4). 360–367. 85 indexed citations
11.
Sabouraud, A., et al.. (1992). Analytical Control Procedures of Immunoreactivity for IgG and Fab Fragments Specific to Haptens. Pharmaceutical Research. 9(5). 643–647. 5 indexed citations
12.
Sandouk, P., et al.. (1991). Morphine pharmacokinetics and pain assessment after intracerebroventricular administration in patients with terminal cancer. Clinical Pharmacology & Therapeutics. 49(4). 442–448. 15 indexed citations
13.
Piechaczyk, Martine, J M Scherrmann, Jill M. Grenier, et al.. (1991). Highly Specific Radioimmunoassay for Digoxin Using a Monoclonal Antibody Selected for Lack of Interference by Digoxin-Like Immunoreactive Substances in Cord Blood Sera. Therapeutic Drug Monitoring. 13(2). 113–119. 9 indexed citations
14.
Urtizberea, M., et al.. (1991). Reversal of murine colchicine toxicity by colchicine-specific Fab fragments. Toxicology Letters. 58(2). 193–198. 15 indexed citations
15.
Urtizberea, M., A. Sabouraud, Olivier Chappey, et al.. (1991). Pharmacokinetics of Total and Free Digoxin and Fab Fragments in 5 Intoxicated Patients after Administration of Specific Anti-Digoxin Fab Fragments. Archives of toxicology. Supplement. 14. 132–135. 5 indexed citations
16.
Chappey, Olivier, Guy Testylier, P. Gourmelon, et al.. (1990). In Vivo Spectrophotometric Determination of Striatal Acetylcholinesterase Activity: The Modulation Induced by the Antidepressant Amitriptyline. Journal of Neurochemistry. 54(1). 333–338. 4 indexed citations
17.
Urtizberea, M., Myriam Rochdi, Frédéric J. Baud, & J M Scherrmann. (1990). Toxicokinetic-toxicodynamic models describing the relation of plasma and red blood cell potassium with plasma digitalis in acute human digitalis poisoning. Toxicology in Vitro. 4(4-5). 526–531. 2 indexed citations
18.
Sabouraud, A., Hélène Denis, M. Urtizberea, Olivier Chappey, & J M Scherrmann. (1990). The effect of nortriptyline-specific active immunization on amitriptyline toxicity and disposition in the rabbit. Toxicology. 62(3). 349–360. 2 indexed citations
19.
Girre, C., et al.. (1989). MODEL‐INDEPENDENT PHARMACOKINETICS OF COLCHICINE AFTER ORAL ADMINISTRATION TO HEALTHY VOLUNTEERS. Fundamental and Clinical Pharmacology. 3(5). 537–543. 19 indexed citations
20.
Thomas, G., et al.. (1989). Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. European Journal of Clinical Pharmacology. 37(1). 79–84. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.M. Scherrmann Breakdown of academic impact, for papers by Bo Odlind Breakdown of academic impact, for papers by Vanya Peltekova Breakdown of academic impact, for papers by Basab K. Mookerjee Breakdown of academic impact, for papers by N. Zöllner Breakdown of academic impact, for papers by John C. Rose Breakdown of academic impact, for papers by T. Sakuma Breakdown of academic impact, for papers by Marc B. Bailie Breakdown of academic impact, for papers by A Gutman Breakdown of academic impact, for papers by W. C. Wise
Rankless by CCL
2026